SCHEMBL3138102

SCHEMBL3138102

O=C(O)Cc1c(F)cccc1[N+](=O)[O-]

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 2/20 0.46
CYP1A2 P05177 3/20 0.45
ALDH1A1 P00352 2/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44
TDP1 Q9NUW8 3/20 0.44
TSHR P16473 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
MAPT P10636 2/20 0.43
AKR1B1 P15121 1/20 0.43
POLB P06746 1/20 0.43
MAPK1 P28482 1/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10686743 1.00 GPR35 (0.46) GPR35CYP1A2ALDH1A1CYP3A4CYP2D6
SCHEMBL15511866 0.90 ALDH1A1 (0.43) GPR35CYP1A2ALDH1A1CYP3A4CYP2D6
SCHEMBL3535123 0.87 GPR35 (0.54) GPR35CYP1A2ALDH1A1TDP1TSHR
SCHEMBL3002755 0.87 ALDH1A1 (0.43) GPR35CYP1A2ALDH1A1CYP3A4CYP2D6
SCHEMBL30625901 0.87 ALDH1A1 (0.43) GPR35CYP1A2ALDH1A1CYP3A4CYP2D6
SCHEMBL4051970 0.85 FBP1 (0.54) GPR35ALDH1A1TSHRMEN1LMNA
SCHEMBL25249470 0.82 GPR35 (0.48) GPR35CYP1A2ALDH1A1CYP3A4CYP2D6
SCHEMBL5500109 0.82 ALDH1A1 (0.49) CYP1A2ALDH1A1CYP3A4CYP2D6HPGD
SCHEMBL503912 0.81 AKR1B1 (0.56) ALDH1A1HPGDMAPTAKR1B1POLB
SCHEMBL28483649 0.80 TDP1 (0.40) GPR35CYP1A2ALDH1A1CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210179578-A1 OX1 ANTAGONISTS HEPTARES THERAPEUTICS LTD (GB) 2021-06-17 US disclosed
US-20210179578-A1 OX1 ANTAGONISTS HEPTARES THERAPEUTICS LTD (GB) 2021-06-17 US disclosed
EP-3710435-A1 OX1 ANTAGONISTS Heptares Therapeutics Limited (GB) 2020-09-23 EP disclosed
EP-2602254-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2017-06-14 EP disclosed
US-9090586-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-07-28 US disclosed
US-20130150344-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-13 US disclosed
EP-2602254-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2013-06-12 EP disclosed
US-7687529-B2 Substituted propylamine derivatives and methods of their use WYETH LLC (US) 2010-03-30 US disclosed
EP-2091933-A1 DIHYDROBENZOFURANYL DERIVATIVES AND METHODS OF THEIR USE Wyeth (US) 2009-08-26 EP disclosed
US-20090099164-A1 Phenylaminopropanol Derivatives and Methods of Their Use WYETH (US) 2009-04-16 US disclosed
EP-1732887-A1 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) Wyeth (US) 2006-12-20 EP disclosed
WO-2006023109-A1 PROGESTERONE RECEPTOR MODULATORS COMPRISING PYRROLE-OXINDOLE DERIVATIVES AND USES THEREOF WYETH (US) 2006-03-02 WO disclosed
WO-2006017075-A1 PROGESTERONE RECEPTOR ANTAGONIST CONTRACEPTIVE REGIMENS AND KITS WYETH (US) 2006-02-16 WO disclosed
US-20060030717-A1 Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof WYETH (US) 2006-02-09 US disclosed
US-20060009509-A1 Progesterone receptor antagonists, contraceptive regimens, and kits WYETH (US) 2006-01-12 US disclosed
WO-2005097744-A1 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) WYETH (US) 2005-10-20 WO disclosed
US-20050222148-A1 Phenylaminopropanol derivatives and methods of their use WYETH (US) 2005-10-06 US disclosed
US-5102667-A Antiallergens, antiinflammatory agents, nervous system disorders, immunology, psychological disorders RHONE-POULENC SANTE (FR) 1992-04-07 US disclosed
US-4721790-A Nucleophilic substitution process for fluoronitroaralkyloxazoline ETHYL CORPORATION (US) 1988-01-26 US disclosed
US-4540795-A Fluoronitroaralkyloxazolines, derivatives thereof, and nucleophilic substitution processes for preparing them ETHYL CORPORATION (US) 1985-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030717-A1 Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof PGR, PGRMC2, PGRMC1 GPR35 103/4885CYP1A2 182/4885ALDH1A1 2361/4885
US-20090099164-A1 Phenylaminopropanol Derivatives and Methods of Their Use PAH, PNMT, COMT GPR35 612/4885CYP1A2 250/4885ALDH1A1 284/4885
US-20050222148-A1 Phenylaminopropanol derivatives and methods of their use PAH, PNMT, COMT GPR35 612/4885CYP1A2 250/4885ALDH1A1 284/4885
US-20210179578-A1 OX1 ANTAGONISTS HCRTR1, HCRTR2, OXTR GPR35 275/4885CYP1A2 1142/4885ALDH1A1 974/4885
US-20060009509-A1 Progesterone receptor antagonists, contraceptive regimens, and kits GNRHR, PGRMC2, PGR GPR35 151/4885CYP1A2 364/4885ALDH1A1 2936/4885
US-20130150344-A1 HETEROCYCLIC COMPOUND PDE5A, PDE3A, PDE3B GPR35 1457/4885CYP1A2 49/4885ALDH1A1 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.